Life Science Nation Newsletter  | August 24,  2017  |  Issue 228

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Aug. 17  - Aug. 23)
Invests Early in Novel Therapeutics, Devices and Life Science Tools
Looks Externally for Neurology and Rare Disease Assets
Invests New $400 Million Fund in Novel Therapeutics and Commercial-Stage Medtech
Invests in Pharmaceuticals and Devices, Interested in 505(b) Repurposed Assets
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
Next Phase Interview: NCI Program Director Todd Haim Explains How RESI Boston Became A Showcase For NIH SBIR Grantees
Todd Haim
Program Director, NCI
Dennis Ford
For the third year in a row, the NIH has sponsored a group of grantees to be part of the RESI Boston Innovation Challenge. This week, Dennis Ford (DF) interviews Program Director Todd Haim (TH) to explore how this relationship benefits the NIH's grantees, and how RESI stands out as a venue for these companies to present.

DF: What is the basic reason NIH is showcasing technology at RESI?

TH: The NIH is supporting the SBIR awardees to showcase their own technologies, and we do this at a variety of industry conferences. And the real goal from the NIH´s perspective is that we realize that we cannot support these companies forever; and that each individual company, in order to reach the patient and the market, will need a lot more funding than can be provided just through SBIR. They will need downstream partners and funders, and it is in our interest to help as much as we can to facilitate those partnerships...

By Natasha Eldridge, Director of RESI Conference Series, LSN

In the last 4 years, RESI has facilitated thousands of new connections between early stage companies and investors, and we often hear of successful partnerships and allocations that have begun at this hub of communication and dialogue. In this article, we'll take a look at one example of a great RESI success.

An early stage therapeutics company was one of 30 companies selected to participate in a RESI Innovation Challenge, out of over 100 applicants. Prior to the event the company used the RESI Partnering software to book a meeting with an investor representing the corporate venture capital fund of a major pharma firm that was looking for assets in their field. Although the startup was a little too early in their development process to match the corporate VC's criteria, the technology was a strong potential fit with the firm's pipeline...

By Lucy Parkinson, Director of Research, LSN

RESI Partnering is now open, providing attendees with the opportunity to book one on one meetings with investors. If you log in to Partnering, you will see a wide variety of investors available to reach out to, including venture capital firms, big pharma, angels - and family offices.

RESI Boston's Biotech Family Office sesssion features family office investors from around the world who are making direct investments into early stage drug development companies. These firms have a variety of strategies, interests and motivations. If you'd like to know how family office investors think about early stage drugs and what kind of technology catches their eye, this is the panel for you.

Moderated by Colin Widen (CEO, Boston Innovation Capital), the panelists are:
  • Christine Bunt (Venture Partner, 20/20 HealthCare Partners)
  • Pini Orbach (Head of Pharma, Arkin Bioventures)
  • Alex Pickett (Principal, Mediqventures)
  • Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital)